Literature DB >> 22024378

Vaginismus: heightened harm avoidance and pain catastrophizing cognitions.

Charmaine Borg1, Madelon L Peters, Willibrord Weijmar Schultz, Peter J de Jong.   

Abstract

INTRODUCTION: Catastrophic appraisal of experienced pain may promote hypervigilance and intense pain, while the personality trait of harm avoidance (HA) might prevent the occurrence of correcting such experiences. Women inflicted with vaginismus may enter a self-perpetuating downward spiral of increasing avoidance of (anticipated) pain. In vaginismus the anticipation of pain may give rise to catastrophic pain ideation. This may establish hypervigilance toward painful sexual stimuli, which consequently results in negative appraisal of sexual cues. This process could impair genital and sexual responding, intensify pain and trigger avoidance, which in turn may contribute to the onset and persistence of symptoms in vaginismus and to certain extent also in dyspareunia. AIMS: To investigate whether women suffering from vaginismus are characterized by heightened levels of habitual pain catastrophic cognitions, together with higher levels of HA.
METHODS: This study consisted of three groups: a lifelong vaginismus group (N = 35, mean age = 28.4; standard deviation [SD] = 5.8), a dyspareunia group (N = 33, mean age = 26.7; SD = 6.8), and women without sexual complaints (N = 54, mean age = 26.5; SD = 6.7). MAIN OUTCOME MEASURES: HA scale of Cloninger's tridimensional personality questionnaire, and the pain catastrophizing scale.
RESULTS: Specifically women inflicted with vaginismus showed significantly heightened levels of catastrophic pain cognitions compared with the other two groups, as well as significant enhanced HA vs. the control group, and a trend vs. the dyspareunia group. Both traits were shown to have cumulative predictive validity for the presence of vaginismus.
CONCLUSION: This study focused on the personality traits of catastrophizing pain cognitions and HA in women with lifelong vaginismus. Our findings showed that indeed, women suffering from vaginismus are characterized by trait of HA interwoven with habitual pain catastrophizing cognitions. This study could help in the refinement of the current conceptualization and might shed light on the already available treatment options for women with vaginismus.
© 2011 International Society for Sexual Medicine.

Entities:  

Mesh:

Year:  2011        PMID: 22024378     DOI: 10.1111/j.1743-6109.2011.02535.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  7 in total

1.  The demographics of pain catastrophizing in a primary care sample.

Authors:  Randy A Sansone; Daron A Watts; Michael W Wiederman
Journal:  Innov Clin Neurosci       Date:  2013-09

Review 2.  A psychosocial approach to female genital pain.

Authors:  Marieke Dewitte; Charmaine Borg; Lior Lowenstein
Journal:  Nat Rev Urol       Date:  2017-11-28       Impact factor: 14.432

3.  Understanding and treating vaginismus: a multimodal approach.

Authors:  Peter T Pacik
Journal:  Int Urogynecol J       Date:  2014-06-04       Impact factor: 2.894

4.  Vaginismus and its correlates in an Iranian clinical sample.

Authors:  F Farnam; M Janghorbani; E Merghati-Khoei; F Raisi
Journal:  Int J Impot Res       Date:  2014-05-15       Impact factor: 2.896

5.  Vaginismus Treatment: Clinical Trials Follow Up 241 Patients.

Authors:  Peter T Pacik; Simon Geletta
Journal:  Sex Med       Date:  2017-03-28       Impact factor: 2.491

6.  [Obstetric outcome of women with primary vaginismus].

Authors:  Elise Tourrilhes; Marie Veluire; David Hervé; Erdogan Nohuz
Journal:  Pan Afr Med J       Date:  2019-04-08

7.  Development and validation of the multidimensional vaginal penetration disorder questionnaire (MVPDQ) for assessment of lifelong vaginismus in a sample of Iranian women.

Authors:  Mitra Molaeinezhad; Robab Latifnejad Roudsari; Alireza Yousefy; Mehrdad Salehi; Effat Merghati Khoei
Journal:  J Res Med Sci       Date:  2014-04       Impact factor: 1.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.